Elevated FBXL6 activates both wild-type KRAS and mutant KRASG12D and drives HCC tumorigenesis via the ERK/mTOR/PRELID2/ROS axis in miceHaojun Xiong(Army Medical University), Chuan‐Ming Xie(Army Medical University)Military Medical ResearchDecember 20, 202310.1186/s40779-023-00501-8Cited by 29SaveCiteExport RISWatch citationsRelated PapersInhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib|Oncology Reports|2019|22Cardiac glycoside bufalin blocks cancer cell growth by inhibition of Aurora A and Aurora B activation via PI3K-Akt pathway|Oncotarget|2018|17